HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
- Conditions
- Nonsquamous Non-small Cell Lung CancerEGFR L858REGFR Exon 19 Deletion
- Interventions
- Drug: Platinum-based chemotherapy
- Registration Number
- NCT05338970
- Lead Sponsor
- Daiichi Sankyo
- Brief Summary
Disease progression is typical for patients with epidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC). Standard platinum-based chemotherapy offers limited efficacy and an unfavorable safety profile.There is an urgent need for more effective and tolerable therapies for patients with EGFRm NSCLC who have exhausted available targeted therapies. Clinical evidence suggest that patritumab deruxtecan constitutes a promising investigational therapy for patients with EGFRm NSCLC.
- Detailed Description
Patritumab deruxtecan (HER3-DXd, U3-1402) is an antibody-drug conjugate (ADC) comprising an anti-HER3 mAb linked to a topoisomerase I inhibitor that is in clinical development for patients with NSCLC, metastatic breast cancer, and colorectal cancer.
The primary objective of the current study is to compare the efficacy of patritumab deruxtecan versus platinum-based chemotherapy, as measured by progression-free survival (PFS) and the key secondary endpoint of overall survival (OS), in participants with metastatic or locally advanced NSCLC with an EGFR-activating mutation (exon 19 deletion or L858R) after failure of third-generation (eg, osimertinib, lazertinib, aumolertinib, alflutinib) EGFR TKI therapy.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 586
-
Is a male or female subject aged ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years old).
-
Has histologically or cytologically documented metastatic or locally advanced non-squamous NSCLC not amenable to curative surgery or radiation.
-
Has documentation of an EGFR-activating mutation detected from tumor tissue or blood sample: exon 19 deletion or L858R at diagnosis or thereafter.
-
Received 1 or 2 prior line(s) of an approved EGFR TKI treatment in the metastatic or locally advanced setting, which must include a third -generation EGFR TKI
-
May have received either neoadjuvant and/or adjuvant treatment if progression to metastatic or locally advanced disease occurred at least 12 months after the last dose of such therapy and subsequently experienced disease progression on or after third-generation EGFR TKI treatment administered in the metastatic or locally advanced setting.
-
Has not received any other prior systemic therapies in the metastatic or locally advanced setting (including chemotherapy, immunotherapy etc) (even if administered in combination with EGFR TKI).
-
Has documentation of radiographic disease progression while receiving or after receiving a third generation EGFR TKI for metastatic or locally advanced disease.
-
Has at least 1 measurable lesion as per RECIST v1.1 by Investigator assessment.
-
Is willing to have a tumor biopsy or provide recently obtained tumor tissue.
-
Has an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 at Screening.
-
Has adequate bone marrow reserve and organ function based on local laboratory evaluation within 14 days prior to randomization:
- Platelet count: ≥100,000/mm^3 or ≥100 × 10^9/L within 14 days prior to the assessment of platelet count during the Screening Period
- Absolute neutrophil count: ≥1500/mm^3 or ≥1.5 × 10^9/L within 14 days prior to the assessment of absolute neutrophil count during the Screening Period
- Hemoglobin (Hgb): ≥9.0 g/dL within 14 days prior to the assessment of hemoglobin during the Screening Period
- Creatine clearance (CrCl): CrCl ≥45 mL/min calculated by using the Cockcroft-Gault equation or measured CrCl
- Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT): AST/ALT ≤3× Upper limit of normal (ULN)
- Total bilirubin (TBL): TBL ≤1.5 × ULN
- Serum albumin: ≥2.5 g/dL
- Prothrombin time (PT) or Prothrombin time-International normalized ratio (PT-INR) and activated partial thromboplastin time (aPTT)/partial thromboplastin time (PTT): ≤1.5 × ULN, except for participants receiving coumarin-derivative anticoagulants or other similar anticoagulant therapy who must have PT-INR within therapeutic range as deemed appropriate by the Investigator
-
Has any previous histologic or cytologic evidence of small cell OR combined small cell/non-small cell disease in the archival tumor tissue or pretreatment tumor biopsy, or squamous NSCLC histology
-
Has any history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis), has current ILD, or is suspected to have such disease by imaging during Screening
-
Has clinically severe respiratory compromise (based on the Investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to the following:
- Any underlying pulmonary disorder, restrictive lung disease, or pleural effusion
- Any autoimmune, connective tissue, or inflammatory disorders where there is documented, or a suspicion of pulmonary involvement at the time of Screening
- OR prior complete pneumonectomy
-
Is receiving chronic systemic corticosteroids dosed at >10 mg prednisone or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to randomization
-
Has any history of or evidence of current leptomeningeal disease
-
Has evidence of clinically active spinal cord compression or brain metastases, defined as being symptomatic and untreated, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms
-
Any prior treatment with any agent including an antibody drug conjugate (ADC) containing a chemotherapeutic agent targeting topoisomerase I, human epidermal growth factor receptor 3 (HER3) antibody, and any systemic therapies (other than EGFR TKIs) in the metastatic/locally advanced setting, including chemotherapy or any other systemic therapy in combination with an EGFR TKI
-
Has history of other active malignancy within 3 years prior to randomization, except for adequately resected nonmelanoma skin cancer, adequately treated intraepithelial carcinoma of the cervix, and any other curatively treated in situ disease
-
Has uncontrolled or significant cardiovascular disease prior to randomization
-
Has active hepatitis B and/or hepatitis C infection, such as those with serologic evidence of active viral infection within 28 days of randomization
-
Has a known human immunodeficiency virus (HIV) infection that is not well controlled
-
Has clinically significant corneal disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Patritumab deruxtecan Patritumab Deruxtecan Participants who will be randomized to receive patritumab deruxtecan (HER3-DXd) 5.6 mg/kg q3W. Platinum-based chemotherapy Platinum-based chemotherapy Participants who will be randomized to receive platinum-based chemotherapy for 4 cycles: pemetrexed plus either cisplatin or carboplatin. Participants without disease progression after 4 cycles of platinum plus pemetrexed therapy may continue treatment with maintenance pemetrexed with no restriction on the number of cycles.
- Primary Outcome Measures
Name Time Method Progression-free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Based on RECIST v1.1 Baseline up to approximately 49 months Progression-free survival (PFS) is defined as the time from the date of randomization to the earlier of the dates of the first documentation of objective progression of disease or death due to any cause.
- Secondary Outcome Measures
Name Time Method Objective Response Rate (ORR) as Assessed by BICR and Investigator Review Based on RECIST v1.1 Baseline up to approximately 49 months Objective response rate (ORR) is defined as the proportion of participants who have a confirmed best overall response (BOR) of complete response (CR) or partial response (PR).
Duration of Response (DoR) as Assessed by BICR and Investigator Review Based on RECIST v1.1 Baseline up to approximately 49 months Duration of response (DoR) is defined as the time from the first documentation of objective response (CR or PR) to the earlier of the dates of the first documentation of objective progression of disease or death due to any cause.
Clinical Benefit Rate (CBR) as Assessed by BICR and Investigator Review Based on RECIST v1.1 Baseline up to approximately 49 months Clinical benefit rate (CBR) will be assessed by BICR and Investigator based on RECIST v1.1. CBR is defined as the proportion of participants who have a confirmed BOR of CR, PR, or stable disease (SD) that lasts for at least 180 days.
Overall Survival (OS) Baseline up to approximately 49 months Overall survival (OS) is defined as the time from the date of randomization to the date of death due to any cause.
Mean Change from Baseline in Patient's Global Impression of Severity Baseline up to approximately 49 months The PGI-S is a one-item questionnaire that contains six response options.
Mean Change from Baseline in EuroQol Questionnaire-5 dimensions-5 levels (EQ-5D-5L) Baseline up to approximately 49 months The EQ-5D-5L is a standardized instrument that will be used for measuring generic health status required for health technology assessments.
Percentage of Participants Who Have Treatment-emergent ADA Baseline up to approximately 49 months The immunogenicity of patritumab deruxtecan will be confirmed by assessing the anti-drug antibodies.
Disease Control Rate (DCR) as Assessed by BICR and Investigator Review Based on RECIST v1.1 Baseline up to approximately 49 months Disease control rate (DCR) is defined as the proportion of participants who have a confirmed BOR of CR, PR, or SD.
Intracranial PFS as Assessed by BICR Baseline up to approximately 49 months Intracranial PFS is defined as the time from the date of randomization to the earlier of the dates of the first documented radiographic intracranial disease progression or death, whichever comes first, as assessed by BICR per CNS-RECIST, in participants with CNS lesion(s) at baseline by BICR per CNS-RECIST.
Mean Change from Baseline in Patient's Global Impression of Change Baseline up to approximately 49 months The PGI-C is a 7-point scale depicting a participant's rating of overall improvement.
Mean Change from Baseline in Patient's Global Impression of Treatment Tolerability Baseline up to approximately 49 months The PGI-TT will capture the patient's overall impression of treatment tolerability.
Mean Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) Baseline up to approximately 49 months The EORTC-QLQ-C30 will assess the patient's overall quality of life (QoL).
Progression-free Survival (PFS) as Assessed by Investigator Review Based on RECIST v1.1 Baseline up to approximately 49 months Progression-free survival (PFS) is defined as the time from the date of randomization to the earlier of the dates of the first documentation of objective progression of disease or death due to any cause.
Time to Response (TTR) as Assessed by BICR and Investigator Review Based on RECIST v1.1 Baseline up to approximately 49 months Time to response (TTR) is defined as the time from the date of randomization to the date of the first documentation of response (CR or PR) that is subsequently confirmed.
Mean Change from Baseline in Non-small Cell Lung Cancer - Symptom Assessment Questionnaire Baseline up to approximately 49 months The NSCLC-SAQ will assess disease-related symptom change in patients with NSCLC.
Progression-free Survival (PFS) as Assessed by Local Standard Clinical Practice Baseline up to approximately 49 months Progression-free survival (PFS) by local standard clinical practice is defined as the time from date of randomization to the documented progression on the first new anticancer therapy (if administered) or death due to any cause, whichever occurred first.
Percentage of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline) Baseline up to approximately 49 months The immunogenicity of patritumab deruxtecan will be confirmed by assessing the anti-drug antibodies.
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Baseline up to approximately 49 months TEAEs will be graded by using National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.
Trial Locations
- Locations (179)
USC Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
Kurume University Hospital
🇯🇵Kurume, Japan
Ospedale Santa Maria della Misericordia
🇮🇹Perugia, Italy
Kindai University Hospital
🇯🇵Ōsaka-sayama, Japan
Fujita Health University Hospital
🇯🇵Toyoake, Japan
Iwakuni Clinical Center
🇯🇵Iwakuni, Japan
Azienda Ospedaliero Universitaria di Parma
🇮🇹Parma, Italy
The Cancer Institute Hospital of JFCR
🇯🇵Koto-Ku, Japan
Hyogo Cancer Center
🇯🇵Akashi, Japan
ASST Sette Laghi
🇮🇹Varese, Italy
Seoul National University Hospital
🇰🇷Seoul, Korea, Republic of
NHO Shikoku Cancer Center
🇯🇵Matsuyama, Japan
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
Hospital Clinic i Provincial de Barcelona
🇪🇸Barcelona, Spain
National Hospital Organization Nagoya Medical Center
🇯🇵Nagoya, Japan
Izumi City General Hospital
🇯🇵Izumi, Japan
Azienda Ospedaliero-Universitaria San Luigi Gonzaga
🇮🇹Orbassano, Italy
Kansai Medical University Hospital
🇯🇵Hirakata, Japan
The Catholic University of Korea, Seoul St. Marys Hospital
🇰🇷Seoul, Korea, Republic of
National Cancer Center
🇰🇷Goyang, Korea, Republic of
IFO Regina Elena
🇮🇹Roma, Italy
Saitama Medical University International Medical Center
🇯🇵Hidaka, Japan
Seoul National University Bundang Hospital
🇰🇷Seongnam, Korea, Republic of
Leiden University Medical Center
🇳🇱Leiden, Netherlands
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
IRCCS Humanitas Research Hospital
🇮🇹Rozzano, Italy
Kanazawa University Hospital
🇯🇵Kanazawa, Japan
Kyushu University Hospital
🇯🇵Fukuoka, Japan
Rijnstate Ziekenhuis
🇳🇱Arnhem, Netherlands
Hospital Universitario Fundacion Jimenez Diaz
🇪🇸Madrid, Spain
Chungbuk National University Hospital
🇰🇷Cheongju-si, Korea, Republic of
Hospital Universitario 12 de Octubre
🇪🇸Madrid, Spain
Erasmus MC
🇳🇱Rotterdam, Netherlands
Leeds Cancer Centre
🇬🇧Leeds, United Kingdom
Hospital Teresa Herrera C.H.U.A.C.
🇪🇸A Coruña, Spain
Severance Hospital
🇰🇷Seoul, Korea, Republic of
The Royal Marsden Hospital NHS Foundation Trust
🇬🇧London, United Kingdom
University Hospital Birmingham NHS Trust
🇬🇧Birmingham, United Kingdom
University Hospitals of Leicester
🇬🇧Leicester, United Kingdom
Tan Tock Seng Hospital
🇸🇬Singapore, Singapore
Hospital del Mar
🇪🇸Barcelona, Spain
Complejo Hospitalario Materno-Insular - Hospital Insular de Gran Canaria
🇪🇸Las Palmas De Gran Canaria, Spain
Hospital Univeritario Marques de Valdecilla
🇪🇸Santander, Spain
Beatson West of Scotland Cancer Centre
🇬🇧Glasgow, United Kingdom
The Royal Wolverhampton NHS Trust
🇬🇧Wolverhampton, United Kingdom
Barts and The London NHS Trust - St Bartholomew s hospital - PET CT Centre
🇬🇧London, United Kingdom
The Royal Marsden NHS Foundation Trust
🇬🇧London, United Kingdom
The Christie Hospital
🇬🇧Manchester, United Kingdom
University of Electronic Science Technology of China UESTC - Sichuan Cancer Hospital Institute Sichuan Provincial Tumor Hospital
🇨🇳Chengdu, China
Union Hospital of Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan, China
Medizinische Universitaet Innsbruck
🇦🇹Innsbruck, Austria
Klinikum Klagenfurt Pulmologie
🇦🇹Klagenfurt, Austria
Instituto Portugues de Oncologio de Lisboa
🇵🇹Lisbon, Portugal
Taichung Veterans General Hospital
🇨🇳Taichung, Taiwan
Onko-Centrum Sp. z o.o.
🇵🇱Lublin, Poland
Med Polonia Sp. z o.o.
🇵🇱Poznań, Poland
Centro Clinico Champalimaud
🇵🇹Lisboa, Portugal
Centro Hospitalar de Vila Nova de Gaia - Espinho
🇵🇹Porto, Portugal
National University Cancer Institute National University Hospital
🇸🇬Singapore, Singapore
ICON Cancer Centre
🇸🇬Singapore, Singapore
Cliniques Universitaires Saint-Luc
🇧🇪Brussels, Belgium
UZ Leuven
🇧🇪Leuven, Belgium
University of Hong Kong/Queen Mary Hospital
🇭🇰Hong Kong, Hong Kong
Oslo University Hospital-The Norwegian Radium Hospital
🇳🇴Oslo, Norway
Stavanger University Hospital
🇳🇴Stavanger, Norway
Centro Hospitalar Universitario do Porto - Hospital de Santo Antonio
🇵🇹Porto, Portugal
E-Da Hospital
🇨🇳Kaohsiung City, Taiwan
Taipei Veterans General Hospital
🇨🇳Taipei, Taiwan
St. Jansdal Ziekenhuis
🇳🇱Harderwijk, Netherlands
Netherlands Cancer Institute
🇳🇱Amsterdam, Netherlands
Akershus University Hospital
🇳🇴Nordbyhagen, Norway
Chang Gung Memorial Hospital-Linkou Branch
🇨🇳Taoyuan, Taiwan
National Taiwan University Hospital NTUH
🇨🇳Taipei, Taiwan
Karl Landsteiner Institut fur Lungenforschung und pneumologische Onkologie c/o Klinik Floridsdorf
🇦🇹Wien, Austria
Prince of Wales Hospital
🇭🇰Hong Kong, Hong Kong
II Klinika Chorob Pluc i Gruzlicy
🇵🇱Białystok, Poland
National Cancer Centre Singapore NCCS
🇸🇬Singapore, Singapore
Kantonsspital Winterthur KSW
🇨🇭Winterthur, Switzerland
National Cheng Kung University Hospital NCKUH
🇨🇳Tainan, Taiwan
Kantonsspital Graubuenden - Hauptstandort
🇨🇭Chur, Switzerland
Saiseikai Kumamoto Hospital
🇯🇵Kumamoto, Japan
Kurashiki Central Hospital
🇯🇵Kurashiki, Japan
Matsusaka Municipal Hospital
🇯🇵Matsusaka, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
National Hospital Organization Hokkaido Cancer Center
🇯🇵Sapporo, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
Sendai Kousei Hospital
🇯🇵Sendai, Japan
Wakayama Medical University Hospital
🇯🇵Wakayama, Japan
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
🇯🇵Tokyo, Japan
MD Anderson Cancer Center
🇪🇸Madrid, Spain
Hospital Regional Universitario Malaga
🇪🇸Málaga, Spain
Hospital Universitario Virgen Macarena
🇪🇸Sevilla, Spain
City of Hope
🇺🇸Duarte, California, United States
Alaska Oncology and Hematology LLC
🇺🇸Anchorage, Alaska, United States
Moores Cancer Center at the UC San Diego Health
🇺🇸La Jolla, California, United States
Highlands Oncology
🇺🇸Springdale, Arkansas, United States
Scripps MD Anderson Cancer Center
🇺🇸La Jolla, California, United States
Kaiser Permanente - Vallejo Medical Center
🇺🇸Vallejo, California, United States
Innovative Clinical Research Institute
🇺🇸Whittier, California, United States
Sarah Cannon/Florida Cancer Specialists - FCS South
🇺🇸Port Charlotte, Florida, United States
Emory University
🇺🇸Atlanta, Georgia, United States
Hackensack Meridian Health-Southern Ocean Medical Center
🇺🇸Manahawkin, New Jersey, United States
The Chris O'Brien Lifehouse
🇦🇺Camperdown, Australia
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Inova Schar Cancer Institute
🇺🇸Fairfax, Virginia, United States
University of Texas Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Sarah Cannon Research Institute
🇺🇸Nashville, Tennessee, United States
Virginia Cancer Specialists
🇺🇸Fairfax, Virginia, United States
St George Public Hospital
🇦🇺Kogarah, Australia
St John of God Subiaco Hospital
🇦🇺Subiaco, Australia
Liverpool Hospital
🇦🇺Liverpool, Australia
Austin Hospital
🇦🇺Melbourne, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Australia
Klinikum Wels-Grieskirchen
🇦🇹Wels, Austria
Landeskrankenhaus Feldkirch
🇦🇹Feldkirch, Austria
AZ Sint Maarten Mechelen
🇧🇪Mechelen, Belgium
William Osler Health System - Brampton Civic Hospital
🇨🇦Brampton, Canada
AZ Delta
🇧🇪Roeselare, Belgium
Peking University Cancer Hospital
🇨🇳Beijing, China
Jilin Cancer Hospital
🇨🇳Chang chun, China
The First Affiliated Hospital Sun-Yat-Sen University
🇨🇳Guangzhou, China
Hunan Cancer Hospital
🇨🇳Changsha, China
National Cancer Center Hospital East
🇨🇳Chibi, China
Guangdong Academy of Medical Science (GAMS) - Guangdong Provincial Peoples Hospital
🇨🇳Guangzhou, China
Fujian Medical University - Union Hospital Foochow Christian Union Hospital
🇨🇳Fuzhou, China
Pecking University Third Hospital
🇨🇳Haidian, China
The First Affiliated Hospital of College of Medicine Zhejiang University
🇨🇳Hangzhou, China
Zhejiang Cancer hospital
🇨🇳Hangzhou, China
Harbin Medical University - Tumor Hospital The Third Affiliated Hospital
🇨🇳Harbin, China
The First Affiliated Hospital - Anhui Medical University Dept of Medical Oncology
🇨🇳Hefei, China
Henan Provincial Peoples Hospital
🇨🇳Henan, China
The Second Affiliated Hospital of Kunming Medical University
🇨🇳Kunming, China
Lin Yi Cancer Hospital
🇨🇳Linyi, China
General Hospital of Eastern Theater Command
🇨🇳Nanjing, China
Fudan University - Shanghai Cancer Center FUSCC
🇨🇳Shanghai, China
The First Affiliated Hospital of Guangxi Medical University
🇨🇳Nanning, China
Cancer Hospital of Shantou University Medical College
🇨🇳Shantou, China
The First Affiliate Hospital of Xi'an Jiaotong University
🇨🇳Xi'an, China
The First Hospital of China Medical University
🇨🇳Shenyang, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Dana-Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Huazhong University of Science and Technology - Tongji Medical College - Tongji Hospital TJH
🇨🇳Wuhan, China
Hopital Morvan CHU de Brest
🇫🇷Brest, France
Centre Francois Baclesse
🇫🇷Caen, France
Centre Leon Berard
🇫🇷Lyon, France
Affiliated Cancer Hospital of Xinjiang Medical University
🇨🇳Ürümqi, China
Montpellier Cancer Institute ICM
🇫🇷Montpellier, France
Centre Hospitalier Lyon Sud
🇫🇷Pierre-Bénite, France
Institut Curie
🇫🇷Paris Cedex 05, France
APHP - Hopital Saint Louis
🇫🇷Paris, France
Centre Hospitalier Universitaire (CHU) de Rennes - Hopital de Pontchaillou
🇫🇷Rennes, France
Institut de Cancrologie de lOuest ICO
🇫🇷Saint-Herblain, France
Gustave Roussy
🇫🇷Villejuif, France
Universitaetsklinikum Essen
🇩🇪Essen, Germany
Klinikum Esslingen GmbH
🇩🇪Esslingen, Germany
IKF Krankenhaus Nordwest
🇩🇪Frankfurt am main, Germany
Asklepios Fachklinik Muenchen-Gauting
🇩🇪Gauting, Germany
Universitatsklinik Giessen und Marburg
🇩🇪Gießen, Germany
Thoraxklinik Heidelberg gGmbH
🇩🇪Heidelberg, Germany
Klinikverbund Allgaeu
🇩🇪Kempten, Germany
LKI Lungenfachklinik Immenhausen
🇩🇪Immenhausen, Germany
Pius-Hospital Oldenburg
🇩🇪Oldenburg, Germany
IRCCS Istituto Oncologico Giovanni Paolo II
🇮🇹Bari, Italy
University G. D'Annunzio Chieti
🇮🇹Chieti, Italy
Ospedale San Luca
🇮🇹Lucca, Italy
IRCCS Istituto Europeo di Oncologia
🇮🇹Milano, Italy
Asst Grande Ospedale Metropolitano Niguarda
🇮🇹Milano, Italy
Hospital General Universitario Gregorio Maranon
🇪🇸Madrid, Spain
LungenClinic Grosshansdorf
🇩🇪Großhansdorf, Germany
St Luke's Cancer Institute
🇺🇸Boise, Idaho, United States
Dartmouth Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States
American Oncology Partners of Maryland
🇺🇸Bethesda, Maryland, United States
Providence Portland Medical Center
🇺🇸Portland, Oregon, United States
University of Wisconsin Carbone Cancer Center
🇺🇸Madison, Wisconsin, United States
Montefiore Medical Center
🇺🇸Bronx, New York, United States
University Medical Center Utrecht
🇳🇱Utrecht, Netherlands
Pamela Youde Nethersole Eastern Hospital
🇭🇰Hong Kong, Hong Kong
Queen Elizabeth Hospital
🇭🇰Hong Kong, Hong Kong